Thus, individuals who have the KIR AA genotype in this population likely have two genomic copies of the strongly inhibiting KIR2DL1 allotype, KIR2DL1*003, and should be best equipped at recognizing and eliminating tumor cells having aberrant C2+HLA-C expression. This evidence concerns the gene C2 and neoplasm.